uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide
Show others and affiliations
2004 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 80, no 4, 244-251 p.Article in journal (Other academic) Published
Abstract [en]

This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120 mg) according to symptom response. Seventy-one patients were treated. Flushing decreased from a mean of 3.0 at baseline to 2.3 on day 1, and 2.0 on day 2, with a daily mean of 2.1 for the first week post-treatment (p < 0.05). Diarrhea decreased from a mean of 5.0 at baseline to 4.3 on day 1 (p < 0.05), and 4.5 on day 2, with a daily mean of 4.4 for the first week post-treatment (p < 0.001). Symptom frequency decreased further after the second and third injections, and reached a plateau after the fourth injection. By month 6, flushing and diarrhea had significantly decreased from baseline by a mean of 1.3 and 1.1 episodes/day, respectively (both p < or = 0.001); 65% of patients with flushing as the target symptom and 18% of diarrhea-target patients achieved > or =50% reduction from baseline. Median urinary 5-hydroxyindoleacetic acid and chromogranin A levels decreased by 24 and 38%, respectively. Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome.

Place, publisher, year, edition, pages
2004. Vol. 80, no 4, 244-251 p.
Keyword [en]
Adult, Aged, Aged; 80 and over, Chromogranins/blood, Comparative Study, Delayed-Action Preparations/*therapeutic use, Dose-Response Relationship; Drug, Drug Administration Schedule, Drug Evaluation/methods, Female, Flushing/drug therapy/physiopathology, Humans, Hydroxyindoleacetic Acid/urine, Male, Malignant Carcinoid Syndrome/complications/*drug therapy/metabolism, Middle Aged, Peptides; Cyclic/blood/*therapeutic use, Quality of Life, Research Support; Non-U.S. Gov't, Somatostatin/*analogs & derivatives/blood/*therapeutic use, Time Factors, Treatment Outcome, Vipoma/drug therapy/physiopathology
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-70003DOI: 10.1159/000082875PubMedID: 15627802OAI: oai:DiVA.org:uu-70003DiVA: diva2:97914
Available from: 2005-04-13 Created: 2005-04-13 Last updated: 2010-10-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15627802&dopt=Citation

Search in DiVA

By author/editor
Eriksson, Barbro
By organisation
Department of Medical Sciences
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 138 hits
ReferencesLink to record
Permanent link

Direct link